Ribomic Inc. (TYO:4591)
87.00
+3.00 (3.57%)
Aug 27, 2026, 2:02 PM JST
Ribomic Revenue
Ribomic had revenue of 4.50M JPY in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to 7.50M, up 650.00% year-over-year. In the fiscal year ending March 31, 2026, Ribomic had annual revenue of 3.00M with 50.00% growth.
Revenue (ttm)
7.50M
Revenue Growth
+650.00%
P/S Ratio
633.35
Revenue / Employee
n/a
Employees
25
Market Cap
4.75B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 3.00M | 1.00M | 50.00% |
| Mar 31, 2025 | 2.00M | - | - |
| Mar 31, 2024 | - | - | - |
| Mar 31, 2023 | 65.00M | -15.00M | -18.75% |
| Mar 31, 2022 | 80.00M | -11.00M | -12.09% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Transgenic Group | 13.64B |
| Kohjin Bio | 4.69B |
| Soiken Holdings | 3.87B |
| Human Metabolome Technologies | 1.42B |
| PRISM BioLab Co.,LTD | 737.27M |
| Kringle Pharma | 342.21M |
| Cyfuse Biomedical K.K. | 305.00M |
| D. Western Therapeutics Institute | 247.00M |